ReviewCurrent neurology and neuroscience reports2016
Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation.
Review in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Subjective sleep disturbances are associated with reduced MRI-derived perivascular-space diffusivity in multiple sclerosis.Journal of neurology · 2026Article
- Phenotyping healthcare use before pediatric-onset multiple sclerosis, including by sex and age: A matched cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Sexual dysfunction in multiple sclerosis: the role of orexin-A and calpain-2 - a pilot study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Adiposity and the first-onset of diagnosed mental illnesses: a population-based cohort study of 10 million UK adults.BMC medicine · 2025Article
- Orexin and Lifestyle Habits: A Meaningful Connection Among Nutrition, Physical Activity, and Sleep Pattern in Health and Diseases.International journal of molecular sciences · 2025Review
- Subchronic Intranasal Administration of NeuroEPO Reduces Long-Term Consequences of Severe Traumatic Brain Injury in Male Rats.Antioxidants (Basel, Switzerland) · 2025Article
- Immunological microenvironment and targeted therapeutics in multiple sclerosis: new insights in crosstalk between immune niches and CNS.Frontiers in immunology · 2025Review
- Understanding the spectrum of non-motor symptoms in multiple sclerosis: insights from animal models.Neural regeneration research · 2024Review
- Thyroid hormone action in adult neurogliogenic niches: the known and unknown.Frontiers in endocrinology · 2024Review
- Overview of the Current Pathophysiology of Fatigue in Multiple Sclerosis, Its Diagnosis and Treatment Options - Review Article.Neuropsychiatric disease and treatment · 2023Review
- Ketogenic diet uncovers differential metabolic plasticity of brain cells.Science advances · 2022Article
- Brain Structural and Functional Alterations in Multiple Sclerosis-Related Fatigue: A Systematic Review.Neurology international · 2022Review
- Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions.World journal of gastroenterology · 2021Review
- The Role of Electroacupuncture in the Regulation of Appetite-Controlling Hormone and Inflammatory Response in Obesity.Medical acupuncture · 2021Review
- Orexinergic System in Neurodegenerative Diseases.Frontiers in aging neuroscience · 2021Review
- Variant-to-Gene-Mapping Analyses Reveal a Role for the Hypothalamus in Genetic Susceptibility to Inflammatory Bowel Disease.Cellular and molecular gastroenterology and hepatology · 2021Article
- Regional microglial activation in the substantia nigra is linked with fatigue in MS.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis.Neural regeneration research · 2020Review
- Insights into the Therapeutic Potential of Glucocorticoid Receptor Modulators for Neurodegenerative Diseases.International journal of molecular sciences · 2020Review
- Multiple sclerosis and sarcoidosis: A case for coexistence.Neurology. Clinical practice · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Signs and symptoms of multiple sclerosis are usually attributed to demyelinating lesions in the spinal cord or cerebral cortex. The hypothalamus is a region that is often overlooked yet controls many important homeostatic functions, including those that are perturbed in multiple sclerosis. In this review we discuss how hypothalamic dysfunction may contribute to signs and symptoms in people with multiple sclerosis. While dysfunction of the hypothalamic-pituitary-adrenal axis is common in multiple sclerosis, the effects and mechanisms of this dysfunction are not well understood. We discuss three hypothalamic mechanisms of fatigue in multiple sclerosis: (1) general hypothalamic-pituitary-adrenal axis hyperactivity, (2) disordered orexin neurotransmission, (3) abnormal cortisol secretion. We then review potential mechanisms of weight dysregulation caused by hypothalamic dysfunction. Lastly, we propose future studies and therapeutics to better understand and treat hypothalamic dysfunction in multiple sclerosis. Hypothalamic dysfunction appears to be common in multiple sclerosis, yet current studies are underpowered and contradictory. Future studies should contain larger sample sizes and standardize hormone and neuropeptide measurements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.